- Home
- ACHV vs CRBP Comparison
ACHV vs CRBP Comparison
Compare ACHV & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACHV
- CRBP
- Stock Information
- Founded
- ACHV N/A
- CRBP 2009
- Country
- ACHV Canada
- CRBP United States
- Employees
- ACHV N/A
- CRBP N/A
- Industry
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- CRBP Biotechnology: Pharmaceutical Preparations
- Sector
- ACHV Health Care
- CRBP Health Care
- Exchange
- ACHV Nasdaq
- CRBP Nasdaq
- Market Cap
- ACHV 72.5M
- CRBP 73.4M
- IPO Year
- ACHV N/A
- CRBP N/A
- Fundamental
- Price
- ACHV $3.58
- CRBP $7.42
- Analyst Decision
- ACHV Strong Buy
- CRBP Strong Buy
- Analyst Count
- ACHV 3
- CRBP 10
- Target Price
- ACHV $14.33
- CRBP $53.56
- AVG Volume (30 Days)
- ACHV 234.9K
- CRBP 114.7K
- Earning Date
- ACHV 05-13-2025
- CRBP 05-06-2025
- Dividend Yield
- ACHV N/A
- CRBP N/A
- EPS Growth
- ACHV N/A
- CRBP N/A
- EPS
- ACHV N/A
- CRBP N/A
- Revenue
- ACHV N/A
- CRBP N/A
- Revenue This Year
- ACHV N/A
- CRBP N/A
- Revenue Next Year
- ACHV N/A
- CRBP $150.00
- P/E Ratio
- ACHV N/A
- CRBP N/A
- Revenue Growth
- ACHV N/A
- CRBP N/A
- 52 Week Low
- ACHV $1.84
- CRBP $4.64
- 52 Week High
- ACHV $5.58
- CRBP $61.90
- Technical
- Relative Strength Index (RSI)
- ACHV 69.97
- CRBP 53.76
- Support Level
- ACHV $2.89
- CRBP $7.05
- Resistance Level
- ACHV $3.32
- CRBP $7.62
- Average True Range (ATR)
- ACHV 0.25
- CRBP 0.50
- MACD
- ACHV 0.06
- CRBP -0.01
- Stochastic Oscillator
- ACHV 95.12
- CRBP 55.97
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.